Amfetamine: Discovery, Development, Safety and Pharmacovigilance

Historical development, monoamine pharmacology, stereoisomers and formulations, current US labelling, abuse-risk communication and practical pharmacovigilance for amfetamine.

Take test

Amfetamine: Discovery, Development, Safety and Pharmacovigilance

Amfetamine is the international nonproprietary name for the synthetic phenethylamine stimulant commonly written amphetamine in United States labelling. The active substance has a much longer therapeutic history than most contemporary attention-deficit/hyperactivity disorder (ADHD) medicines. Its clinical value in selected conditions must be assessed alongside dose-dependent sympathomimetic effects, psychiatric and cardiovascular vulnerability, diversion, misuse and dependence. The distinction between prescribed exposure and nonmedical use is essential, but neither should be dismissed when assessing a serious safety report [1–4].

1. Historical development: chemistry preceded modern ADHD diagnosis

Lazăr Edeleanu synthesised the compound in 1887, but did not establish its modern therapeutic use. Subsequent investigators, including Gordon Alles in the late 1920s, examined amphetamine's physiological stimulant effects during attempts to find alternatives to ephedrine. Smith, Kline & French developed and marketed Benzedrine products in the 1930s. Early indications and commercial practices included decongestion, wakefulness, depression and other conditions; these historic uses must not be mistaken for present-day approved indications [3,4].

The 1937 work of Charles Bradley with children experiencing behavioural and educational difficulties was an important observation in the eventual development of stimulant treatment for what is now classified as ADHD. Bradley's patient population and diagnostic categories differed from modern ADHD definitions. The historical literature also documents expanding nonmedical consumption, military use and later recognition of dependence and toxicity [3–5].

An important scientific distinction is that the molecule was not originally designed through today's disease-specific, randomised paediatric drug-development model. Clinical indications, evidence standards, controlled-substance frameworks and risk communication evolved after its introduction.

2. Molecular identity and stereochemistry

Amfetamine has one chiral centre, producing dextroamfetamine (d-amphetamine) and levoamfetamine (l-amphetamine) enantiomers. The racemate contains both. Dextroamfetamine is a separate INN and warrants its own product-specific article. A mixed-salt formulation may contain both enantiomers in a specified ratio; it is not interchangeable with a racemic amfetamine sulfate tablet merely because the total mass or brand family seems similar [3,6].

This distinction has immediate pharmacovigilance consequences. A report of a product switch must record the exact active ingredients, salt, dosage form, strength and release characteristics. A switch between immediate-release and extended-release products can alter the time course of adverse events. Combination-derived prescription figures must not be allocated in full to both amfetamine and dexamfetamine; the B015/B016 queue positions are prioritisation devices, not substance-specific utilisation estimates.

3. Mechanism: transporter substrates, not just reuptake inhibitors

Amfetamine increases central dopaminergic and noradrenergic signalling. It acts at monoamine transport systems, enters presynaptic terminals and promotes increased extracellular catecholamines through transporter-mediated and intracellular processes, including vesicular redistribution. The resulting effects on attention, arousal, wakefulness, appetite, pulse and blood pressure are linked but are not equivalent clinical outcomes [3,7].

Unlike a selective serotonin reuptake inhibitor, amfetamine's core stimulant action cannot be adequately described as blocking one serotonin transporter. Its peripheral sympathomimetic activity is also clinically relevant. Therapeutic improvement in attention does not prove that ADHD is simply a measurable dopamine-deficiency state, nor does a stimulant response alone establish the diagnosis.

Drug exposure is affected by the product's release system and physiological variables including urinary pH; acidic urine generally increases excretion and alkaline urine reduces it. These principles help explain interactions and variability but do not justify unsupervised attempts to manipulate drug elimination [1,7].

4. Regulatory products and indication boundaries

A current US amfetamine sulfate tablet label provides indications for ADHD, narcolepsy and a restricted short-term adjunctive role in exogenous obesity, subject to the exact product's instructions [1]. The Evekeo amfetamine sulfate label provides product-specific wording and paediatric dosing information [2]. The historical use of Benzedrine or Dexedrine does not establish current authorisation for the same formulation in every country.

The FDA also publishes labels for mixed salts of a single-entity amphetamine product. Those products contain multiple salts and both d- and l-enantiomers and require separate product-specific interpretation [6]. The UK/European availability and legal status of racemic amfetamine preparations should not be inferred from US DailyMed. A UK dexamfetamine product is not proof that racemic amfetamine has the same national marketing authorisation.

Product context Substance identity Key regulatory caution
Racemic amfetamine sulfate tablet Both amfetamine enantiomers Check its own US label and age/indication wording
Dexamfetamine product Dextro-enantiomer Separate INN and label; not interchangeable
Mixed amphetamine salts Multiple salts containing both enantiomers Combination formulation and release system matter
Lisdexamfetamine Prodrug of dexamfetamine Different active-substance identity and kinetics

The purpose of the table is to prevent ingredient and formulation attribution errors, not to rank these products as therapeutically equivalent [1,2,6].

5. Clinical benefit and limitations of extrapolation

Stimulants can reduce core ADHD symptoms in appropriately selected patients, with response assessed against attention, impulsivity, hyperactivity and functional outcomes. Trial results for a particular mixed-salt extended-release product should not be described as a direct randomised result for racemic amfetamine sulfate. Likewise, benefits in narcolepsy cannot be generalised to ordinary fatigue, sleep deprivation or every hypersomnolence disorder [1,6,8].

ADHD treatment commonly requires longitudinal assessment: baseline diagnostic validity, coexisting anxiety, sleep and substance-use disorders, school/work functioning, dose response, tolerability and ongoing need. A response to stimulant treatment is one component of clinical management rather than proof that a medication should be continued indefinitely without review.

The historic obesity indication in some US labels reflects a narrowly limited adjunctive role and must not be conflated with modern evidence and authorisations for long-term obesity pharmacotherapy [1,2]. In a PV article, clinical trial efficacy, historical marketing and current local authorisation are distinct evidence categories.

6. The contemporary boxed warning and why it matters

The US FDA updated class-wide prescription-stimulant warnings in May 2023 to make risks of misuse, abuse, addiction and overdose more prominent. The communication also emphasised appropriate prescribing, secure storage and avoiding sharing prescription medicines [1,2,9]. An important pharmacovigilance distinction is between treatment as prescribed, a medication error, nonmedical use and a substance use disorder. These categories can overlap but are not synonyms.

The 2025 Evekeo and 2026 amfetamine sulfate labels identify a high potential for abuse and misuse, with potentially severe outcomes [1,2]. This warning does not erase the therapeutic benefit of indicated treatment, nor establish that every patient develops addiction. Safety narratives should describe actual circumstances without stigmatising patients.

7. Cardiovascular effects

Increased heart rate and blood pressure are expected sympathomimetic effects, but serious cardiovascular events require separate medical assessment. Product information cautions against treatment in patients with certain serious cardiac diseases [1,2]. Assess pre-existing disease, family history, clinical examination, baseline and follow-up vital signs, the timing of treatment changes, and other medicines. A modest measured pulse increase and a confirmed arrhythmia are different safety phenotypes.

When reports describe chest pain, collapse or suspected arrhythmia, collect ECG findings and the clinical diagnosis where available. Spontaneous reporting cannot establish a population incidence rate without reliable exposure denominators.

8. Psychiatric and neurological reactions

New or worsening psychotic or manic symptoms, agitation, sleep disruption and tics are clinically important [1,2]. The underlying disorder, sleep deprivation and other medicines may complicate causality. Record the exact symptoms, functional impairment, temporal relationship and clinician's diagnosis. Insomnia alone is not a diagnosis of mania; anxiety alone is not a diagnosis of psychosis.

9. Growth and appetite in children

Reduced appetite and weight change are familiar stimulant effects. Product information recommends monitoring growth during prolonged paediatric treatment [1,2]. Height, weight and growth trajectory should be assessed in the context of baseline measurements, nutritional status, chronic illness and the clinical indication. A single low weight measurement does not establish permanent growth suppression.

10. Peripheral vasculopathy and tics

Peripheral vasculopathy, including Raynaud's phenomenon, is a labelled warning [1,2]. Case follow-up should establish changes in finger colour, discomfort, temperature sensitivity, severity and alternative vascular explanations. Tic symptoms require a history of previous motor or vocal tics, family history, natural symptom fluctuation and other neuropsychiatric treatments.

11. Interactions and serotonin syndrome

The referenced labels warn of serotonin syndrome when amfetamine is used with certain serotonergic medicines, including antidepressants. Monoamine oxidase inhibitors are subject to explicit contraindications and product-specific timing restrictions [1,2]. CYP2D6 inhibition may affect exposure. A medically useful suspected case records the full medication list, timing, temperature, neuromuscular examination, mental-state changes and alternative diagnoses. Do not infer a confirmed syndrome from nonspecific agitation alone.

Context Main safety question Useful follow-up
Serotonergic co-medication Is there a clinically supported serotonin syndrome? Exact co-medications, chronology, examination
Cardiac comorbidity Is the event haemodynamic or structural? BP, pulse, ECG, cardiac history
Psychiatric comorbidity Is the presentation new or pre-existing? Baseline symptoms, diagnosis, clinical timeline
Paediatric long-term treatment Is growth trajectory affected? Serial measurements, nutrition, duration
Product change Is the formulation or ingredient composition different? Dispensed product, prescribed schedule, chronology

12. Pregnancy and breastfeeding

Reproductive safety evaluation should distinguish therapeutic exposure, maternal illness, other medicines and obstetric factors. The exact marketed product's label should guide local decisions [1,2]. Collect gestational timing, dose, relevant maternal conditions, neonatal findings and follow-up. An adverse outcome temporally following exposure does not by itself establish causation.

13. Pharmacovigilance begins with correct product identity

Amfetamine safety reports require an exact description of the marketed product. A report naming only a familiar brand family may conceal differences in active ingredients, enantiomers, salts or release formulation. The record should identify the label, strength, dosage form, prescribed schedule, actual exposure, relevant changes and all concomitant medicines.

A case of palpitations following a product change cannot be interpreted well without confirming whether the patient received a different release formulation or combination of ingredients. Similarly, a reported psychiatric reaction requires a clinical phenotype rather than a generic term such as ā€œbehaviour change.ā€

14. Medical follow-up by suspected event

Event Priority information Important alternatives
Tachycardia or hypertension Baseline and serial vital signs, ECG if indicated Fever, anxiety, other medicines
Chest pain or arrhythmia Clinical diagnosis, ECG, cardiac history Underlying cardiac disease
Psychosis or mania Symptom description, diagnosis, treatment timeline Psychiatric illness, sleep deprivation
Serotonin syndrome Neuromuscular findings, temperature, interacting medicines Infection, other toxidromes
Growth concern Serial height and weight, nutritional context Baseline growth pattern, chronic illness
Pregnancy outcome Gestational exposure, maternal history, infant findings Obstetric and co-medication factors

These are recommended follow-up fields, not additional legal ICSR validity criteria.

Illustrative case: cardiovascular symptoms

A patient develops palpitations shortly after a prescription change. The assessment should establish which product was dispensed, whether the dose or formulation changed, the patient's prior cardiovascular history, vital signs, ECG findings if available and other relevant treatments. A temporal relationship justifies investigation but not an automatic causal conclusion. This is a hypothetical teaching example.

Illustrative case: behavioural change

A child receiving treatment for ADHD develops worsening insomnia and irritability. The report should include baseline behaviour, sleep patterns, dose history, school and family observations and any concurrent illness. If psychosis or mania is suspected, seek specific diagnostic information rather than coding nonspecific symptoms as confirmed serious psychiatric syndromes.

15. Medication errors and governance

The pharmacovigilance and medication-safety systems should be able to distinguish a suspected adverse reaction from a dispensing or administration error, a quality complaint and an event involving exposure outside the prescribed regimen. Each can be relevant to prevention, but the applicable reporting route and legal criteria depend on the jurisdiction and facts.

Signal evaluation must consider stimulated reporting, changes in prescribing volume, differences in product formulation and the medical quality of reports. A spontaneous reporting count is not an incidence estimate. A QPPV should be able to trace case intake, medical review, duplicate handling, follow-up, aggregate assessment, escalation and regulatory decisions, while coordinating with quality and medication-error functions as appropriate.

The FDA's 2023 class-wide communication provides an example of how safety language may be strengthened without claiming identical absolute risks for every stimulant product [9]. Risk communication should preserve access to appropriate treatment while making the serious risks and safe handling of prescribed medicine understandable.

16. Key takeaways

Amfetamine's lifecycle runs from early chemical synthesis through the development of stimulant treatment and contemporary condition-specific product authorisations. The pharmacology involves central catecholamine signalling and peripheral sympathomimetic effects. Racemic amfetamine, dexamfetamine, mixed-salt combinations and prodrugs must be distinguished. The principal pharmacovigilance domains are cardiovascular and psychiatric effects, growth and appetite, interactions, reproductive exposure and the FDA's prominent warnings on misuse and addiction. Product-level evidence, actual exposure and medical confirmation are more useful than generic class labels.

References

  1. DailyMed. Amphetamine sulfate tablets, US prescribing information, updated July 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26dbad66-13c4-4906-88b3-ab7ee191466c&version=14
  2. DailyMed. Evekeo (amphetamine sulfate tablets), US prescribing information, updated October 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156
  3. Heal DJ et al. Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol. 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3666194/
  4. Rasmussen N. Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses. Int Rev Neurobiol. 2015;120:9–25. https://doi.org/10.1016/bs.irn.2015.02.001
  5. Bradley C. The behavior of children receiving Benzedrine. Am J Psychiatry. 1937;94:577–585. https://doi.org/10.1176/ajp.94.3.577
  6. DailyMed. Mixed salts of a single-entity amphetamine product, extended-release capsules, US label. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b21fd4-8d0b-4e54-a35d-8ad84a7caa78
  7. Sulzer D et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005. https://pubmed.ncbi.nlm.nih.gov/?term=Sulzer+Mechanisms+neurotransmitter+release+amphetamines+2005
  8. Cortese S et al. Comparative efficacy and tolerability of medications for ADHD in children, adolescents and adults: systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
  9. FDA. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. Drug Safety Communication, 11 May 2023. https://www.fda.gov/drugs/drug-safety-communications/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions

Regulatory Note

Educational review prepared 22 October 2026. Amfetamine is the international nonproprietary spelling corresponding to ā€œamphetamineā€ in US labelling. The source labels are US product-specific documents; they do not establish authorisation in every other jurisdiction. Clinical findings, regulatory warnings and recommended pharmacovigilance practices are different evidence categories. Illustrative cases are not actual safety reports.

Revision History

Last reviewed: 2026-10-22

QPPV.com